X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/27/2852892/0/en/Santhera-Announces-NDA-for-Vamorolone-in-Duchenne-Muscular-Dystrophy-Accepted-and-Granted-Priority-Review-by-China-s-NMPA.html
https://www.globenewswire.com//news-release/2024/03/14/2845975/0/en/Santhera-s-Partner-Catalyst-Pharmaceuticals-Launches-AGAMREE-Vamorolone-in-the-United-States.html
https://www.globenewswire.com//news-release/2024/02/14/2828764/0/en/Santhera-Announces-Publication-of-Efficacy-Safety-and-Tolerability-Data-with-Vamorolone-AGAMREE-in-Patients-with-Duchenne-Muscular-Dystrophy-in-Neurology.html
https://www.globenewswire.com//news-release/2024/01/15/2808933/0/en/Santhera-Launches-AGAMREE-Vamorolone-in-Germany-as-First-Market-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2024/01/12/2808425/0/en/Santhera-Receives-Approval-for-AGAMREE-Vamorolone-as-a-Treatment-for-Duchenne-Muscular-Dystrophy-in-the-United-Kingdom.html
https://www.globenewswire.com//news-release/2023/12/18/2797461/0/en/Santhera-s-AGAMREE-Vamorolone-Approved-in-the-European-Union-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com/news-release/2023/12/07/2792212/0/en/Santhera-Appoints-Executive-Committee-Members-as-it-Transitions-into-Commercial-Stage.html
https://www.globenewswire.com//news-release/2023/10/27/2768135/0/en/Santhera-Receives-U-S-FDA-Approval-of-AGAMREE-vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2023/10/13/2759744/0/en/Santhera-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-AGAMREE-vamorolone-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2023/09/07/2738968/0/en/Santhera-Announces-Half-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
Market Place
Share 
